Fast Five Quiz: Castration-Resistant Prostate Cancer

Kyle A. Richards, MD


December 02, 2020

As the fifth most common cause of cancer death in men worldwide, prostate cancer is largely identified in patients who are asymptomatic. For the most part, prostate cancer-related deaths occur as a result of advanced disease, which results from any combination of lymphatic, hematogenous, or contiguous local spread. In spite of early responses to treatment with androgen deprivation therapy, most patients eventually progress to castration-resistant prostate cancer (CRPC). The treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) has seen stepwise improvement since 2002, when it was shown that zoledronic acid could reduce skeletal-related event incidence. Non-metastatic castration-resistant prostate cancer (nmCRPC) is only seen in about 4% to 7% of patients with prostate cancer. Three pivotal trials, SPARTAN, PROSPER, and ARAMIS, have examined treatment strategies for this subgroup of patients.

How much do you know about the presentation, workup, and treatment of mCRPC and nmCRPC? Test your knowledge with this quick quiz.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.